Table 4. Adverse events related to sorafenib before and 2 months after discontinuation of sorafenib.

	Before discontinuation			2 months after discontinuation
Adverse events	Test (n = 102)	Control (n = 55)	P	Control (n = 55)	P
Hand-foot skin reaction	72(70.6)	36(64.5)	0.789	8(14.5)	<0.001
Grade 1–2	61(59.8)	31(56.4)		8(14.5)
Grade 3–4	11(10.8)	5(9.1)		0
Diarrhoea	52(50.9)	27(49.1)	0.853	0	<0.001
Grade 1–2	44(43.1)	24(43.6)		0
Grade 3–4	8(7.8)	3(5.5)		0
Hypertension	4(3.9)	2(3.6)	0.309	0	0.361
Grade 1–2	4(3.9)	1(1.8)		0
Grade 3–4	0	1(1.8)		0
Alopecia			0.345		0.004
Grade 1–2	39(38.2)	24(43.6)		10(18.2)
Weight loss			0.924		0.039
Grade 1–2	40(39.2)	22(40)		12(21.8)
Fatigue			0.797		0.002
Grade 1–2	35(34.3)	20(36.4)		6(10.9)

Note- data are numbers of patients, data in parentheses are percentages.